EPO-R+ Myelodysplastic Cells with Ring Sideroblasts Produce High Erythroferrone Levels to Reduce Hepcidin Expression in Hepatic Cells.

Shogo Miura,Masayoshi Kobune,Hiroto Horiguchi,Shohei Kikuchi,Satoshi Iyama,Kazuyuki Murase,Akari Goto,Hiroshi Ikeda,Kohichi Takada,Koji Miyanishi,Junji Kato
DOI: https://doi.org/10.1016/j.bcmd.2019.04.014
2019-01-01
Abstract:Recently, a new erythroid regulator, erythroferrone (ERFE), which downregulates hepatic hepcidin production, has been identified. However, the relationship between ERFE and abnormal iron metabolism in MDS is unclear. In this study, we examined the level of ERFE mRNA during ex vivo erythroid differentiation using cord blood CD34+ cells and we further analyzed whether ERFE could be produced by MDS cells using a public database (GSE58831). ERFE mRNA was increased during normal erythroid differentiation. An analysis of GSE58831 indicated that ERFE expression in bone marrow (BM) MDS cells was higher than that in healthy volunteer (HV)-derived BM cells. ERFE expression significantly and positively correlated with the expression of erythropoietin (EPO) receptors (EPO-R), ALAS2 (5'-Aminolevulinate Synthase 2), STEAP3 (STEAP family member 3) and the presence of ring sideroblasts or the SF3B1 mutation. These results suggest that EPO-R+ MDS cells with ring sideroblasts or an SF3B1 mutation produce high levels of ERFE that may be associated with a reduction in hepcidin.
What problem does this paper attempt to address?